Axon Enterprise (NASDAQ:AXON) Price Target Raised to $725.00

Axon Enterprise (NASDAQ:AXON) had its target price upped by investment analysts at JMP Securities from $610.00 to $725.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price target suggests a potential upside of 10.33% from the company’s current price.

AXON has been the subject of several other reports. Northland Securities raised their price objective on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Robert W. Baird lifted their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday, January 27th. TD Cowen began coverage on shares of Axon Enterprise in a report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price target for the company. Finally, Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $542.15.

Axon Enterprise Stock Down 0.2 %

AXON stock traded down $1.02 during mid-day trading on Tuesday, hitting $657.09. 257,316 shares of the company were exchanged, compared to its average volume of 573,077. The company has a market capitalization of $50.10 billion, a PE ratio of 169.79, a price-to-earnings-growth ratio of 6.54 and a beta of 1.05. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. Axon Enterprise has a twelve month low of $252.20 and a twelve month high of $698.67. The firm has a fifty day simple moving average of $620.41 and a 200 day simple moving average of $486.16.

Insiders Place Their Bets

In other news, insider Jeffrey C. Kunins sold 21,834 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $593.88, for a total value of $12,966,775.92. Following the sale, the insider now directly owns 154,394 shares of the company’s stock, valued at approximately $91,691,508.72. This trade represents a 12.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total value of $271,831.50. Following the completion of the sale, the director now directly owns 6,929 shares in the company, valued at approximately $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,545 shares of company stock valued at $30,721,337 over the last ninety days. Corporate insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds and other institutional investors have recently made changes to their positions in the business. IFP Advisors Inc lifted its stake in Axon Enterprise by 7.6% during the fourth quarter. IFP Advisors Inc now owns 952 shares of the biotechnology company’s stock worth $566,000 after purchasing an additional 67 shares during the period. Colonial River Investments LLC raised its stake in shares of Axon Enterprise by 5.5% in the fourth quarter. Colonial River Investments LLC now owns 1,573 shares of the biotechnology company’s stock valued at $935,000 after acquiring an additional 82 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Axon Enterprise by 16.2% in the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 12,200 shares of the biotechnology company’s stock valued at $7,251,000 after acquiring an additional 1,700 shares during the last quarter. Howard Capital Management Inc. bought a new position in shares of Axon Enterprise in the fourth quarter valued at approximately $313,000. Finally, WESPAC Advisors LLC bought a new position in shares of Axon Enterprise in the fourth quarter valued at approximately $897,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.